Combating cancer immunotherapy resistance: a nano‐medicine perspective
Cancer Communications · 2025-07 · 45 (7) · 813-840
DOI: 10.1002/cac2.70025 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Communications, online erschienen am 10.04.2025. Verfasst von Xiangyi Kong und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medic…. Hauptthemen laut MEDLINE: Immunotherapy, Neoplasms, Nanoparticles, Nanomedicine. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: China National Key R&D (Research and Development) Program, Natural Science Foundation of China, CAMS Innovation Fund for Medical Sciences.
Abstract (Originalsprache)
Cancer immunotherapy offers renewed hope for treating this disease. However, cancer cells possess inherent mechanisms that enable them to circumvent each stage of the immune cycle, thereby evading anti‐cancer immunity and leading to resistance. Various functionalized nanoparticles (NPs), modified with cationic lipids, pH‐sensitive compounds, or photosensitizers, exhibit unique physicochemical properties that facilitate the targeted delivery of therapeutic agents to cancer cells or the tumor microenvironment (TME). These NPs are engineered to modify immune activity. The crucial signal transduction pathways and mechanisms by which functionalized NPs counteract immunotherapy resistance are outlined, including enhancing antigen presentation, boosting the activation and infiltration of tumor‐specific immune cells, inducing immunogenic cell death, and counteracting immunosuppressive conditions in the TME. Additionally, this review summarizes current clinical trials involving NP‐based immunotherapy. Ultimately, it highlights the potential of nanotechnology to advance cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.
- Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shen…
- Department of Skin and Breast Tumor, University Clinical Hospital No. 4 affiliated with the First Moscow State Medical University named after I.M. Sechenov, Moscow, Russia Federation.
ORCID-Profile: Xiangyi Kong, Xintong Xie, Jidong Gao, Jing Wang
Förderung
- China National Key R&D (Research and Development) Program
- Natural Science Foundation of China
- CAMS Innovation Fund for Medical Sciences
- Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences
- Young Elite Scientist Sponsorship Program By BAST
- Beijing Association for Science and Technology's "Golden-Bridge Seed Funding Program"
- Beijing Hope Run Special Fund of Cancer Foundation of China
- Chinese Young Breast Experts Research project
Zitieren
APA
Kong, X., Xie, X., Wu, J., Wang, X., Zhang, W., Wang, S., Abbasova, D. V., Fang, Y., Jiang, H., Gao, J., & Wang, J. (2025). Combating cancer immunotherapy resistance: a nano‐medicine perspective. Cancer Communications, 45(7), 813-840. https://doi.org/10.1002/cac2.70025
Vancouver
Kong X, Xie X, Wu J, Wang X, Zhang W, Wang S, et al. Combating cancer immunotherapy resistance: a nano‐medicine perspective. Cancer Communications. 2025;45(7):813-840. doi:10.1002/cac2.70025
BibTeX
@article{Kong2025,
author = {Kong, Xiangyi and Xie, Xintong and Wu, Juan and Wang, Xiangyu and Zhang, Wenxiang and Wang, Shuowen and Abbasova, Daria Valerievna and Fang, Yi and Jiang, Hongnan and Gao, Jidong and Wang, Jing},
title = {Combating cancer immunotherapy resistance: a nano‐medicine perspective},
journal = {Cancer Communications},
year = {2025},
volume = {45},
number = {7},
pages = {813--840},
doi = {10.1002/cac2.70025}
}
EUVIMED